New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

The Era of Precision Oncology

Springer Healthcare IME

J. Schneider

New Frontiers in NSCLC Treatment: Expanding Options Beyond Chemo-Imm…

Giannis Mountzios

Landscape of Biomarker Testing for NSCLC

Springer Healthcare IME

F. López-Ríos

Patient Selection for Targeted Therapy in BRAF V600E NSCLC

Robert Hsu

WCLC 2024 Insights: Addition of Cytotoxic Chemotherapy to Targeted T…

Insights from 2024 WCLC

B. Pellini

NSCLC & Targeted Therapy: A Brief Overview and Update in the Metasta…

Memorial Sloan Kettering Cancer Center

M. Hwang

The Changing Prognosis of Lung Cancer Brain Metastases

MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis

S. Goldberg

Year in Review: Precision Medicine

Vivek Subbiah

Precision Medicine in NSCLC

UChicago Medicine 12th International Clinical Cancer Genomics Conference

S. Gray

Practical Guidelines on Testing & Treatment of BRAF V600+ NSCLC

Fred Hutchinson Cancer Center

C. Baik

Evolving Landscape of Targeted Therapies

Springer Healthcare IME

L. Hendriks

Efficacy and Safety of Encorafenib & Binimetinib in BRAF V600-Mutant…

Nagla Abdel Karim

Strategies for Managing Toxicities of Oral Oncolytics in Lung Cancer…

UNC Lineberger Comprehensive Cancer Center

K. Chen, A. Faso, B. Patel

Progress in the Treatment of NSCLC

Yale Cancer Center

R. Herbst

Options for BRAF-Mutated NSCLC Patients

MI&T Congressi

D. Planchard

ELCC 2024 Insights: "Small Numbers, Big Impact - The Importance of T…

Insights from ELCC 2024

L. Brcic

Best of ASCO® 2024: ADCs in NSCLC

ecancer

E. Santos​

BRAF as a Positive Predictive Biomarker in NSCLC

Umberto Malapelle